Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ZAP70 | P43403 | 9/20 | 0.68 |
| ▸ | ALK | Q9UM73 | 8/20 | 0.62 |
| ▸ | IGF1R | P08069 | 3/20 | 0.62 |
| ▸ | AXL | P30530 | 2/20 | 0.62 |
| ▸ | CDC7 | O00311 | 2/20 | 0.62 |
| ▸ | PLK4 | O00444 | 2/20 | 0.62 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.62 |
| ▸ | AURKA | O14965 | 2/20 | 0.62 |
| ▸ | DCLK1 | O15075 | 2/20 | 0.62 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.62 |
| ▸ | JAK2 | O60674 | 2/20 | 0.62 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.62 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.62 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.62 |
| ▸ | PAK4 | O96013 | 2/20 | 0.62 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.62 |
| ▸ | EGFR | P00533 | 2/20 | 0.62 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.62 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.62 |
| ▸ | PRKCG | P05129 | 2/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12729336 | 1.00 | ZAP70 (0.68) | ZAP70ALKIGF1RAXLCDC7 | |
| SCHEMBL1912110 | 0.99 | ZAP70 (0.69) | ZAP70ALKIGF1RAXLCDC7 | |
| SCHEMBL12729507 | 0.93 | ULK1 (0.67) | ZAP70ALKIGF1RAXLCDC7 | |
| SCHEMBL4089533 | 0.91 | ZAP70 (0.64) | ZAP70ALKIGF1RAXLCDC7 | |
| SCHEMBL1912109 | 0.91 | AXL (0.66) | ZAP70ALKIGF1RAXLCDC7 | |
| SCHEMBL12729347 | 0.91 | AXL (0.66) | ZAP70ALKIGF1RAXLCDC7 | |
| SCHEMBL1912006 | 0.90 | AXL (0.67) | ZAP70ALKIGF1RAXLCDC7 | |
| SCHEMBL4099214 | 0.86 | ULK1 (0.57) | ZAP70ALKIGF1RAXLCDC7 | |
| SCHEMBL4096235 | 0.85 | ZAP70 (0.65) | ZAP70ALKIGF1RAXLCDC7 | |
| SCHEMBL4100010 | 0.85 | ZAP70 (0.65) | ZAP70ALKIGF1RAXLCDC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090131436-A1 | Pyrimidine Derivatives | NOVARTIS AG (CH) | 2009-05-21 | — | — | US | claimed |
| EP-1784392-A2 | PYRIMIDINE DERIVATIVES | Novartis AG (CH) | 2007-05-16 | — | — | EP | claimed |
| WO-2006021454-A2 | PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2006-03-02 | — | — | WO | claimed |
| US-20110098280-A1 | 2,4-PYRIMIDINEDIAMINES USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES, INFLAMMATORY AND IMMUNE SYSTEM DISORDERS | NOVARTIS AG (CH) | 2011-04-28 | — | — | US | disclosed |
| EP-2287156-A1 | 2,4-Di(phenylamino)-pyrimidines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders | Novartis AG (CH) | 2011-02-23 | — | — | EP | disclosed |
| US-7893074-B2 | inhibition of focal adhesion kinase or/and IGF-1 Receptor; for example: 2-[2-(2,5-Dimethoxy-phenylamino)-5-nitro-pyrimidin-4-ylamino]-N-methyl-benzenesulfonamide | NOVARTIS AG (CH) | 2011-02-22 | — | — | US | disclosed |
| US-7893074-B2 | inhibition of focal adhesion kinase or/and IGF-1 Receptor; for example: 2-[2-(2,5-Dimethoxy-phenylamino)-5-nitro-pyrimidin-4-ylamino]-N-methyl-benzenesulfonamide | NOVARTIS AG (CH) | 2011-02-22 | — | — | US | disclosed |
| US-20090131436-A1 | Pyrimidine Derivatives | NOVARTIS AG (CH) | 2009-05-21 | — | — | US | disclosed |
| US-20080132504-A1 | 2, 4-Pyrimidinediamines Useful In The Treatment Of Neoplastic Diseases, Inflammatory And Immune System Disorders | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2008-06-05 | — | — | US | disclosed |
| US-20080132504-A1 | 2, 4-Pyrimidinediamines Useful In The Treatment Of Neoplastic Diseases, Inflammatory And Immune System Disorders | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2008-06-05 | — | — | US | disclosed |
| EP-1784392-A2 | PYRIMIDINE DERIVATIVES | Novartis AG (CH) | 2007-05-16 | — | — | EP | disclosed |
| WO-2006021454-A2 | PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2006-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098280-A1 | 2,4-PYRIMIDINEDIAMINES USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES, INFLAMMATORY AND IMMUNE SYSTEM DISORDERS | TYMS, TYMP, DPYD | ZAP70 341/4885ALK 3384/4885IGF1R 4627/4885 |
| US-20080132504-A1 | 2, 4-Pyrimidinediamines Useful In The Treatment Of Neoplastic Diseases, Inflammatory And Immune System Disorders | TYMS, TYMP, DPYD | ZAP70 302/4885ALK 3200/4885IGF1R 4633/4885 |
| US-20090131436-A1 | Pyrimidine Derivatives | DPYD, TYMP, TYMS | ZAP70 1678/4885ALK 2060/4885IGF1R 4608/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.